Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus - Scorecard - MDSpire

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus

  • By

  • Borja del Carmelo Gracia Tello

  • José Miguel García-Bruñén

  • Luis Corredor

  • Natalia Allue Fantova

  • Eva Ma Calvo Beguería

  • Rubén García-Muñío

  • Laura Pérez Abad

  • Jimena Aramburu Llorente

  • Beatriz Martinez Muriel

  • Paula Vidales Miguélez

  • Roxanna Alexandra Morante Mendoza

  • Julia Martínez Artigot

  • Noelia Chicano Nieto

  • Jorge Álvarez Troncoso

  • Luis Martinez-Lostao

  • Adela Marín Ballvé

  • May 8, 2026

  • 0 min

Share

Clinical Scorecard: Increased Levels of Interleukin-6 as Indicators of Short-Term Flares in Systemic Lupus Erythematosus

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults diagnosed with SLE, particularly those at risk of flares, including details on age and demographics.
Care Setting

Key Highlights

  • additional_metrics

Guideline-Based Recommendations

Diagnosis

    Management

    • S
    • p
    • e
    • c
    • i
    • f
    • y
    • i
    • n
    • t
    • e
    • r
    • v
    • e
    • n
    • t
    • i
    • o
    • n
    • s
    • o
    • r
    • t
    • r
    • e
    • a
    • t
    • m
    • e
    • n
    • t
    • a
    • d
    • j
    • u
    • s
    • t
    • m
    • e
    • n
    • t
    • s
    • b
    • a
    • s
    • e
    • d
    • o
    • n
    • I
    • L
    • -
    • 6
    • l
    • e
    • v
    • e
    • l
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Suggest potential treatment options or adjustments based on IL-6 monitoring.

        Clinical Best Practices

        • evidence

        Related Resources & Content

        Original Source(s)

        Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus

        • by Borja del Carmelo Gracia Tello, José Miguel García-Bruñén, Luis Corredor, Natalia Allue Fantova, Eva Ma Calvo Beguería, Rubén García-Muñío, Laura Pérez Abad, Jimena Aramburu Llorente, Beatriz Martinez Muriel, Paula Vidales Miguélez, Roxanna Alexandra Morante Mendoza, Julia Martínez Artigot, Noelia Chicano Nieto, Jorge Álvarez Troncoso, Luis Martinez-Lostao, Adela Marín Ballvé

        • May 8, 2026

        Related Content

        EULAR Updates Behçet’s Syndrome Recommendations

        EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

        Botulinum Toxin Evaluated in Digital Ischemia

        Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

        FDA Reshapes Drug Testing Approach

        The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.